Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients

Pharmacogenomics Journal

Volumn 18, Issue 1, 2018, Pages 29-34

  Ning, Y ^a   Zhang, W ^a   Hanna, D L ^a   Yang, D ^a   Okazaki, S ^a   Berger, M D ^a   Miyamoto, Y ^a   Suenaga, M ^a   Schirripa, M ^a   El Khoueiry, A ^a   Lenz, H J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRIVANIB; CELECOXIB; CETUXIMAB; CYTOKERATIN 20; EPOTHILONE B; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; MESSENGER RNA; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PRI 724; PROTEIN KINASE B BETA; SURVIVIN; TWIST RELATED PROTEIN 1; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CIRCULATING TUMOR CELL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; CLINICAL TRIAL; COLORECTAL TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROGRESSION-FREE SURVIVAL;

EID: 84981266818     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2016.62     Document Type: Article

References (31)

1. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-6904.
2. Molnar B, Ladanyi A, Tanko L, Sreter L, Tulassay Z. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 2001; 7: 4080-4085.
3. Aggarwal C, Meropol NJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol 2013; 24: 420-428.
4. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 3213-3221.
5. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 1223-1229.
6. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
7. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 2013; 19: 1438-1449.
8. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009; 11: R46.
9. Gazzaniga P, Gradilone A, Petracca A, Nicolazzo C, Raimondi C, Iacovelli R et al. Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. J Cell Mol Med 2010; 14: 2073-2077.
10. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013; 339: 580-584.
11. Sastre J, Maestro ML, Puente J, Veganzones S, Alfonso R, Rafael S et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 2008; 19: 935-938.
12. Tol J, Koopman M, Miller MC, Tibbe A, Cats A, Creemers GJ et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 2010; 21: 1006-1012.
13. Steinert G, Scholch S, Niemietz T, Iwata N, Garcia SA, Behrens B et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res 2014; 74: 1694-1704.
14. Yokobori T, Iinuma H, Shimamura T, Imoto S, Sugimachi K, Ishii H et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res 2013; 73: 2059-2069.
15. Wharton RQ, Jonas SK, Glover C, Khan ZA, Klokouzas A, Quinn H et al. Increased detection of circulating tumor cells in the blood of colorectal carcinoma patients using two reverse transcription-PCR assays and multiple blood samples. Clin Cancer Res 1999; 5: 4158-4163.
16. Wong SC, Chan CM, Ma BB, Hui EP, Ng SS, Lai PB et al. Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res 2009; 15: 1005-1012.
17. Iinuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol 2011; 29: 1547-1555.
18. Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R et al. Cytokeratin-20 and survivin expressing circulating tumor cells predict survival in metastatic colorectal cancer patients by a combined immunomagnetic qRT-PCR approach. Mol Cancer Ther 2015; 14: 2401-2408.
19. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-142.
20. Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, Xiao SY et al. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci USA 2008; 105: 20315-20320.
21. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567.
22. Shook D, Keller R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech Dev 2003; 120: 1351-1383.
23. Barbazan J, Muinelo-Romay L, Vieito M, Candamio S, Diaz-Lopez A, Cano A et al. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer. Int J Cancer 2014; 135: 2633-2643.
24. Zeuner A, Todaro M, Stassi G, De Maria R. Colorectal cancer stem cells: from the crypt to the clinic. Cell Stem Cell 2014; 15: 692-705.
25. Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelialmesenchymal transition. J Cell Biol 2005; 171: 1023-1034.
26. Kim YH, Kim G, Kwon CI, Kim JW, Park PW, Hahm KB. TWIST1 and SNAI1 as markers of poor prognosis in human colorectal cancer are associated with the expression of ALDH1 and TGF-beta1. Oncol Rep 2014; 31: 1380-1388.
27. Deng Y, Zhou J, Fang L, Cai Y, Ke J, Xie X et al. ALDH1 is an independent prognostic factor for patients with stages II-III rectal cancer after receiving radiochemotherapy. Br J Cancer 2014; 110: 430-434.
28. Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 2013; 57: 1458-1468.
29. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 2012; 14: R15.
30. Mikolajczyk SD, Millar LS, Tsinberg P, Coutts SM, Zomorrodi M, Pham T et al. Detection of EpCAM-negative and cytokeratin-negative circulating tumor cells in peripheral blood. J Oncol 2011; 2011: 252361.
31. Grover PK, Cummins AG, Price TJ, Roberts-Thomson IC, Hardingham JE. Circulating tumour cells: The evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann Oncol 2014; 25: 1506-1516.